Skip to main content


A CME/CE Webinar

Click the PRETEST button at the bottom of the page to begin the registration process!

If you have already registered, thank you!

You will receive an email confirmation of your registration with further details.

Original Release: March 25, 2020
Expiration: March 31, 2021

George T. Grossberg, MD (Chair)
Samuel W. Fordyce Professor
Director, Geriatric Psychiatry
Department of Psychiatry and Behavioral Neuroscience
St Louis University School of Medicine
St Louis, Missouri

Jeffrey L. Cummings, MD, ScD
Director, Center for Neurodegeneration and Translational Neuroscience
Director Emeritus, Lou Ruvo Center for Brain Health
Cleveland Clinic
Las Vegas, Nevada

Elaine R. Peskind, MD
Friends of Alzheimer’s Research Professor of Psychiatry
Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Co-Director, VA Northwest Mental Illness Research, Education, and Clinical Center
VA Puget Sound Health Care System
Seattle, Washington


Program Overview
A case-based program CME/CE Webinar that will address best practices, emerging treatments, and clinical pearls for the diagnosis and management of dementia-related psychosis (DRP).

Target Audience
This activity intends to educate psychiatrists, physician assistants, nurses, social workers, and psychologists caring for patients with DRP.

Learning Objectives
Upon completion of this activity, participants will be better able to:

  • Apply best practices in assessment and diagnosis of DRP 
  • Interpret recent clinical trial data for the treatment of DRP
  • Develop evidence-based, safe treatment plans for persons with DRP

To Obtain CME/CE Credit
To obtain CME/CE credit for this activity, read the material in its entirety and consult referenced sources as necessary. Please take this post test and evaluation online. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it. There are no fees for participating in and receiving credit for this activity.

Physicians and Nurses: In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Association for Geriatric Psychiatry. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Successful completion of this program qualifies for up to 1.5 AMA PRA Category 1 Credits™ for physicians and 1.5 contact hours for nurses.

Psychology Education:
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Social Workers:
As a Jointly Accredited Organization, Amedco is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Amedco maintains responsibility for this course. Social workers completing this course receive 1.5 continuing education credits.

Grantor Statement
This continuing medical education activity is supported through an unrestricted educational grant from ACADIA Pharmaceuticals Inc.

Jeffrey L. Cummings, MD, ScD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Stock Shareholder: Adamas Pharmaceuticals, Inc; Annovis Bio; Bioasis Technologies, Inc; MedAvante-ProPhase, Inc; and United Neuroscience; Consultant: ACADIA Pharmaceuticals Inc; Actinogen; AgeneBio, Inc; Alkahest, Inc; Alzheon, Inc; Annovis Bio; Avanir Pharmaceuticals, Inc; Axsome Therapeutics, Inc; Biogen Idec; Cassava Sciences, Inc; Cerecin Inc; Cerevel Therapeutics, LLC; Cognoptix Inc; Cortexyme; EIP Pharma, Inc; Eisai Inc; F. Hoffmann-La Roche Ltd; Foresight; GreenValley Inc; Grifols; Hisun USA, Inc; Idorsia Pharmaceuticals Ltd; Karuna Therapeutics; Nutricia; Orion Corporation; Otsuka America Pharmaceutical, Inc; ReMYND; Resverlogix; Samumed, LLC; Samus Therapeutics, Inc; Third Rock Ventures; Signant Health; Sunovion Pharmaceuticals Inc; Suven Life Sciences Limited; United Neuroscience; and Vivoryon Therapeutics AG; Other Financial or Material Support: CNS Innovations LLC.

George T. Grossberg, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Research Grant Site Principal Investigator: F. Hoffmann-La Roche Ltd; and Janssen Global Services, LLC; Consultant: ACADIA Pharmaceuticals Inc; Alkahest, Inc; Avanir Pharmaceuticals, Inc; BioXcel Therapeutics; H. Lundbeck A/S; Otsuka America Pharmaceutical, Inc; and Takeda Pharmaceuticals USA, Inc; Other Financial or Material Support (Safety Monitoring Committee): EryDel SPA; and Newron Pharmaceuticals SPA.

Elaine R. Peskind, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of Research Grant Site Principal Investigator: Eli Lilly and Company; Stock Shareholder: Bristol-Myers Squibb Company; Scientific/Medical Advisory Board Member: ACADIA Pharmaceuticals Inc; and Avanir Pharmaceuticals, Inc.

Editorial Support Disclosures
Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; and Michelle Ong have no relevant commercial relationships to disclose.

Disclosure Attestation

The contributing physicians listed above have attested to the following:
  1. that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
  2. that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
  3. that all reasonable clinical alternatives will be discussed when making practice recommendations.

Off-Label Discussion
This educational activity might contain discussion of evidence-based and/or investigational uses of agents that are not indicated by the FDA. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the official prescribing information for each product.

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the American Association for Geriatric Psychiatry, MedEdicus LLC, or ACADIA Pharmaceuticals Inc.

This CME/CE activity is copyrighted to MedEdicus LLC © 2020. 216